Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myelom...

Oncology Data Advisor™ · Highlights from the San Antonio Breast Cancer Symposium At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Devel...

Wow! 2022 has been an exciting year of new challenges, amazing successes, and incredible opportunities. And we couldn't have gotten through it all without YOU! Before we wrap up the top stories and new features from OncData this year, we want to take time to thank each and every one of YOU: doctors, nurses, medical staff, and all frontline workers for your continued dedication. You continue to inspire us each and every day. THANK YOU!

Oncology Data Advisor™ · CLL Society, a Valuable Resource for Patients and the Health Care Team: Brian Koffman, MD In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them. 

Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holst...

Oncology Data Advisor™ · Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be prese...

Oncology Data Advisor™ · Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.  

At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares...

Are you attending the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans this weekend? Come visit Oncology Data Advisor and ConveyMED while you are there! We will be attending and conducting live interviews discussing the latest research, news, and updates from the conference. Visit us in the press area outside of rooms 256-257...

In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).  

With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and empha...

In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them.

Oncology Data Advisor™ · Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.  

In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.  

Oncology Data Advisor™ · Recent Updates in Waldenstrom Macroglobulinemia With Morie Gertz, MD In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the Mayo Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.

In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the Mayo Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia (WM) session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.  

Oncology Data Advisor™ · Staying Up To Date On Treatment of Myelofibrosis With John Mascarenhas, MD Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. 

Oncology Data Advisor™ · Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usuall...

Oncology Data Advisor™ · Understanding Clonal Hematopoiesis With Rahul Banerjee, Jeremy Meier, and Samuel Rubinstein Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies. 

Oncology Data Advisor™ · The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can foc...